Congress funds cancer research with tobacco tariff revenue, prioritizing rare and pediatric cancers.
H.R. 10093 — Cancer Research Trust Fund Act · Filed by Ashley Hinson (R-IA) · Introduced Aug 13, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a dedicated trust fund for cancer research, funded by 10% of federal tariff revenue collected on imported tobacco and tobacco substitute products. The Department of Health and Human Services, in coordination with the Defense Health Agency, would use the money to fund research into cancer screening, prevention, treatments, and therapies, with priority given to rare cancers and pediatric cancers.
Why we flagged it
The bill's operative mechanism is straightforward: it dedicates a revenue stream to a specific public-health research mission. There are no liability shields, carve-outs, or private beneficiaries named. The mechanism is transparent and the purpose is stated plainly.
What the text implies
- The bill does not specify how much total funding will flow to the Fund in any given year, since it depends on tariff collection rates and import volumes, which fluctuate. Actual research capacity may vary significantly year to year.
- The coordination requirement with the Defense Health Agency is unusual for a civilian cancer research program and may signal military medical research applications, though the bill does not elaborate on that role.
- The bill authorizes but does not mandate appropriations, meaning Congress retains discretion to fund the trust or leave it unfunded despite the tariff revenue being collected.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill dedicates new federal revenue to cancer research without cutting existing programs or restricting citizen rights. Citizens benefit from expanded research capacity into screening, prevention, and treatment, with explicit priority for rare and pediatric cancers. The funding mechanism (tobacco tariffs) is transparent and does not impose new costs on the general public.
Who stands to gain
- academic medical centers and research institutions
- pharmaceutical and biotech companies conducting cancer research
- medical device manufacturers developing diagnostic and therapeutic tools
Named in the bill
Department of Health and Human Services, Defense Health Agency, Secretary of the Treasury, Secretary of War, Cancer Research Trust Fund
Where it stands
- Aug 13, 2026 — Introduced · Congress.gov: “Introduced in House”
- Aug 13, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,310 characters) on Aug 15, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress funds cancer research with tobacco tariff revenue, prioritizing rare and pediatric cancers.” QuorumCivic. https://share.quorumcivic.app/bill/119/hr10093 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.